Visteon Corp (VC) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently underperforming due to weak financial performance, insider selling, and a lack of positive catalysts. While there is a chance for short-term price recovery, the long-term outlook is clouded by disappointing guidance and reduced analyst price targets. Holding off on investment until clearer positive signals emerge is recommended.
The technical indicators suggest a bearish trend. The MACD is negative and contracting, RSI is neutral at 27.492, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is currently trading near its S1 support level of 89.283, with resistance at 91.993.

NULL identified. No recent news or significant positive developments. Analysts note some potential for recovery in 2027, but this is speculative.
Insider selling has increased significantly, up 6958.69% over the last month.
Analysts have lowered price targets citing disappointing 2026 guidance, reduced sales expectations, and program cancellations.
Weak financial performance in Q4 2025, with net income and EPS dropping over 90% YoY.
In Q4 2025, revenue increased slightly by 0.96% YoY to $948 million. However, net income dropped by 90.28% YoY to $14 million, EPS fell by 90.12% YoY to 0.51, and gross margin declined by 9.81% to 12.87%. Overall, the financial performance indicates significant challenges.
Analysts have lowered price targets across the board, with JPMorgan reducing its target to $110 from $118 and maintaining a Neutral rating. Other firms like Baird, RBC Capital, Deutsche Bank, UBS, and TD Cowen have also reduced targets but maintain mixed ratings ranging from Neutral to Buy. Analysts cite disappointing 2026 guidance and reduced sales expectations as key reasons for the downgrades.